Clinical trial Recruiting at 1 site Observational Ages 1 Month to 15

How well beta-lactam antibiotics reach tissue in critically ill children

Official title: TACTIC Study: Tissue Penetration of Antibiotics in CriTically Ill Children

Run by University Hospital, Ghent · NCT07822243 · Data updated 2026-11-12

This study tests whether three common beta-lactam antibiotics reach sufficient tissue levels in the muscles of critically ill children.

Quick facts

Study typeObservational
Ages1 Month to 15 Years
SexAll
Enrollment60 (estimated)
SponsorUniversity Hospital, Ghent
Academic / other
Locations1 site (Ghent)
StatusRecruiting
StartedOctober 1, 2021
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedSeptember 16, 2026
Trial IDNCT07822243 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are critically ill children aged 1 month to 15 years in the PICU who require one of the three study antibiotics and have appropriate vascular access.

Probably not a fit

Patients whose clinical course does not involve the studied antibiotics or who cannot undergo microdialysis may not benefit from the study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational pharmacokinetic study in a single center. It uses microdialysis to measure unbound antibiotic concentrations in interstitial tissue fluid during initial dosing and at steady state in pediatric patients with critical illness who are receiving piperacillin-tazobactam, meropenem, or amoxicillin-clavulanic acid. The study also looks at how patient characteristics affect antibiotic disposition in muscle tissue. Microdialysis catheters are placed in muscle with continuous analgesia for sampling, alongside blood measurements to compare tissue and plasma levels. The goal is to see if tissue drug levels meet predefined pharmacokinetic/pharmacodynamic targets to inform dosing in this vulnerable population.

Why it matters

Potential benefit: If successful, the findings could help tailor antibiotic dosing to achieve effective tissue concentrations in critically ill children, potentially improving treatment outcomes.

How similar studies have gone: Prior adult studies suggest tissue levels can differ from plasma levels, but pediatric tissue PK data are limited and this study is among the first in this population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient admitted to the Pediatric Intensive Care Unit (PICU).
* Age: 1 month to 15 years.
* Receiving intravenous antibiotic treatment with piperacillin-tazobactam, meropenem, or amoxicillin-clavulanic acid.
* Receiving continuous analgosedation (required for microdialysis catheter insertion; if analgosedation is stopped after insertion, the catheter may remain in place).
* Intra-arterial (preferred) or intravenous access available for blood sampling.

Exclusion Criteria:

* Presence of coagulopathy and/or thrombocytopenia:

  * Platelet count \< 50,000/µL
  * International Normalized Ratio (INR) \> 1.5
  * Activated partial thromboplastin time (aPTT) \> 1.5 x upper limit of normal value (age-specific thresholds: \> 50 sec for 30-90 days; \> 42 sec for 90-180 days; \> 38 sec for \> 180 days)
* Personal or family history of excessive bleeding.
* Current treatment with coumarin derivative anticoagulants.
* Known hypersensitivity to beta-lactam antibiotics.
* Pregnancy.
* Absence of parental (or legal guardian) informed consent.
* Absence of suitable catheter for blood sampling.

Where it's running

  • Ghent University Hospital
    Ghent, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.